PTC Operating Income from 2010 to 2024

PTCT Stock

USD 45.11 0.90 1.96%

PTC Therapeutics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit PTC Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2004-12-31

Previous Quarter

-33.4 M

Current Value

-54.5 M

Quarterly Volatility

47.7 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 135.6 M, Total Revenue of 984.7 M or Research Development of 699.9 M, as well as many indicators such as Price To Sales Ratio of 2.09, Dividend Yield of 0.0 or Days Sales Outstanding of 51.74. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.

Check out the analysis of PTC Therapeutics Correlation against competitors.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

Latest PTC Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of PTC Therapeutics over the last few years. Operating Income is the amount of profit realized from PTC Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of PTC Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. PTC Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

PTC Operating Income Regression Statistics

	Arithmetic Mean	(178,432,970)
	Coefficient Of Variation	(90.08)
	Mean Deviation	135,503,610
	Median	(132,058,000)
	Standard Deviation	160,734,656
	Sample Variance	25835.6T
	Range	470.5M
	R-Value	(0.91)
	Mean Square Error	4914.6T
	R-Squared	0.82
	Slope	(32,612,916)
	Total Sum of Squares	361698.8T

PTC Operating Income History

	2024	-331.9 M
	2023	-349.4 M
	2022	-439.9 M
	2021	-374.9 M
	2020	-397.9 M
	2019	-192.8 M
	2018	-115.7 M

Other Fundumenentals of PTC Therapeutics

Non Operating Income Net Other

PTC Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.24	0.66	0.65	0.67	0.92	0.78	0.27	0.48	-0.87	0.86	0.94	0.51	0.89	-0.85	0.94	0.81	0.24	0.69	0.84	0.93
Total Stockholder Equity	-0.24		0.0	-0.79	0.23	-0.6	-0.57	-0.01	-0.84	0.65	-0.63	-0.35	-0.64	-0.08	0.61	-0.29	-0.7	-0.46	-0.26	-0.08	-0.52
Accounts Payable	0.66	0.0		0.14	0.49	0.54	0.6	0.4	-0.01	-0.56	0.59	0.52	0.21	0.74	-0.6	0.69	0.45	0.2	0.03	0.43	0.62
Long Term Debt	0.65	-0.79	0.14		0.14	0.85	0.65	-0.09	0.95	-0.88	0.84	0.78	0.81	0.49	-0.76	0.61	0.91	0.41	0.7	0.5	0.76
Short Term Investments	0.67	0.23	0.49	0.14		0.46	0.42	0.37	0.03	-0.35	0.27	0.68	0.24	0.57	-0.25	0.58	0.26	0.38	0.46	0.86	0.57
Total Liab	0.92	-0.6	0.54	0.85	0.46		0.87	0.22	0.74	-0.98	0.96	0.91	0.68	0.76	-0.95	0.88	0.95	0.37	0.67	0.72	0.97
Property Plant Equipment	0.78	-0.57	0.6	0.65	0.42	0.87		0.63	0.5	-0.86	0.85	0.71	0.73	0.67	-0.87	0.77	0.76	0.45	0.4	0.51	0.88
Current Deferred Revenue	0.27	-0.01	0.4	-0.09	0.37	0.22	0.63		-0.24	-0.16	0.17	0.1	0.3	0.23	-0.26	0.25	-0.01	0.27	-0.07	0.11	0.28
Net Debt	0.48	-0.84	-0.01	0.95	0.03	0.74	0.5	-0.24		-0.76	0.72	0.65	0.68	0.29	-0.65	0.45	0.83	0.45	0.6	0.42	0.64
Retained Earnings	-0.87	0.65	-0.56	-0.88	-0.35	-0.98	-0.86	-0.16	-0.76		-0.99	-0.88	-0.73	-0.78	0.95	-0.88	-0.97	-0.4	-0.63	-0.63	-0.94
Net Receivables	0.86	-0.63	0.59	0.84	0.27	0.96	0.85	0.17	0.72	-0.99		0.83	0.67	0.78	-0.98	0.86	0.95	0.3	0.56	0.56	0.91
Total Current Assets	0.94	-0.35	0.52	0.78	0.68	0.91	0.71	0.1	0.65	-0.88	0.83		0.65	0.82	-0.77	0.87	0.85	0.39	0.77	0.88	0.92
Short Term Debt	0.51	-0.64	0.21	0.81	0.24	0.68	0.73	0.3	0.68	-0.73	0.67	0.65		0.46	-0.57	0.5	0.66	0.56	0.5	0.34	0.61
Common Stock	0.89	-0.08	0.74	0.49	0.57	0.76	0.67	0.23	0.29	-0.78	0.78	0.82	0.46		-0.75	0.94	0.67	0.23	0.59	0.67	0.78
Net Tangible Assets	-0.85	0.61	-0.6	-0.76	-0.25	-0.95	-0.87	-0.26	-0.65	0.95	-0.98	-0.77	-0.57	-0.75		-0.86	-0.91	-0.24	-0.51	-0.52	-0.9
Capital Surpluse	0.94	-0.29	0.69	0.61	0.58	0.88	0.77	0.25	0.45	-0.88	0.86	0.87	0.5	0.94	-0.86		0.8	0.33	0.69	0.77	0.91
Long Term Debt Total	0.81	-0.7	0.45	0.91	0.26	0.95	0.76	-0.01	0.83	-0.97	0.95	0.85	0.66	0.67	-0.91	0.8		0.32	0.63	0.6	0.91
Short Long Term Debt	0.24	-0.46	0.2	0.41	0.38	0.37	0.45	0.27	0.45	-0.4	0.3	0.39	0.56	0.23	-0.24	0.33	0.32		0.31	0.41	0.43
Net Invested Capital	0.69	-0.26	0.03	0.7	0.46	0.67	0.4	-0.07	0.6	-0.63	0.56	0.77	0.5	0.59	-0.51	0.69	0.63	0.31		0.77	0.64
Net Working Capital	0.84	-0.08	0.43	0.5	0.86	0.72	0.51	0.11	0.42	-0.63	0.56	0.88	0.34	0.67	-0.52	0.77	0.6	0.41	0.77		0.79
Capital Stock	0.93	-0.52	0.62	0.76	0.57	0.97	0.88	0.28	0.64	-0.94	0.91	0.92	0.61	0.78	-0.9	0.91	0.91	0.43	0.64	0.79

Click cells to compare fundamentals

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-349.4 M	-331.9 M
Non Operating Income Net Other	-44.3 M	-42.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PTC Operating Income from 2010 to 2024

Latest PTC Therapeutics' Operating Income Growth Pattern

PTC Operating Income Regression Statistics

PTC Operating Income History

Other Fundumenentals of PTC Therapeutics

PTC Therapeutics Operating Income component correlations

About PTC Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for PTC Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY